
Transforming ALS Diagnosis and Drug Discovery
Breakthrough diagnosis and treatments
—reimagining ALS care with cutting-edge technology.
Scroll
About SONoALS
Mission-Driven Science
SONoALS, Inc. is a pioneering startup to redefine how ALS is diagnosed and treated. Our mission is to bring non-invasive, data-rich monitoring to the frontlines of neurodegenerative disease research. The team unites clinical neuroscience and biomedical engineering to make that mission a reality.
Breakthrough Technology
Wearable Ultrasound × AI-Powered Analysis
Revolutionary ultrasound technology combined with AI-powered analysis for Amyotrophic Lateral Sclerosis (ALS) monitoring and diagnosis.

Wearable Ultrasound Device Prototype
- Minimized ultrasound probe via a hub, allowing direct attachment to the skin
- Connectable to a laptop for simultaneous 4-muscle measurement & recording for 20 minutes in a resting state
- Acquired data is sent to the AI analysis server to display results

Overall View
詳細を見る
Probe & Hub Close-up
詳細を見る
Probe Close-up 1
詳細を見る
Probe Close-up 2
詳細を見るApplication & Measurement Images

Attachment State 1
詳細を見る
Attachment State 2
詳細を見る
Attachment State 3
詳細を見るPrecision Tools for ALS Research and Beyond
Transforming healthcare through innovative applications in early diagnosis and drug discovery.

Applications
Early and Non-invasive Diagnosis of ALS
- Fasciculations are one of the signs that appear earlier than needle EMG abnormalities.
Drug Discovery Support
Fasciculation biomarkers responding in days
- Pre-clinical drug screening in humans
- Selection of responder groups
- Significant reduction in clinical trial enrollment duration
We aim to realize these goals.
News & Press
Latest updates and achievements from SONoALS
Selected for Tokyo's Advanced Medical Device Acceleration Project (AMDAP)
SONoALS's project "Development of an ALS early-diagnosis and drug-discovery support platform using AI wearable ultrasound for long-duration, simultaneous multi-muscle observation" was selected for the FY2026 cohort of the Tokyo Metropolitan Government's Advanced Medical Device Acceleration Project (AMDAP).
Pitched at "Metabolites - Miracle Molecules" Co-hosted by Stellar Science Foundation
SONoALS delivered a pitch at "Metabolites - Miracle Molecules," an international networking event held on the opening night of BioJapan at Stellar Science Foundation, BASEGATE Yokohama Kannai.
CEO Saeki Gave an Invited Lecture at Fukui Prefectural Hospital's Intractable Disease Training Seminar
At the FY2026 1st Intractable Disease Training Seminar ("Latest ALS Updates and Compassionate Patient Support") held at Fukui Prefectural Hospital, CEO Saeki gave an invited lecture on the latest ALS treatments and what patients hope for from their supporters.
FAQ
Answers to questions we are frequently asked
The information on this page concerns technology under research and development and is subject to change.
Get in Touch
Ready to learn more about our revolutionary ALS technology? Let's connect.
Company Information
Address
WALLSQUARE Kitanozaka
2-13-15 Yamamoto Ave., Chuo Ward
Kobe City, Hyogo 650-0003, Japan
Established
May 2025


Tadashi Kojima (Applied Information Technology Engineer, Healthcare Information Technologist)
CTO/COO, SONoALS
LinkedIn Profile